# OnCo record paper-doebele-entrectinib-ntrk-lancet-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-doebele-entrectinib-ntrk-lancet-oncol-2020" ;
  schema:name "Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials"@en ;
  schema:description "Entrectinib, a TRK and ROS1 inhibitor that enters the brain, shrank tumours in more than half of patients with NTRK fusion-positive cancers of ten types and controlled brain metastases, leading to a tumour-agnostic approval alongside larotrectinib."@en ;
  schema:url <https://onco.cc/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(19)30691-6>, <https://pubmed.ncbi.nlm.nih.gov/31838007/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(19)30691-6> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Doebele RC, Drilon A, Paz-Ares L, et al." ;
  onco:cancers <https://onco.cc/cancers/ntrk-fusion-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/entrectinib/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .